用激酶组学治疗肿瘤新进展(3)
 |
| 第1页 |
参见附件(1867KB，3页)。
[7] Wood ER,Truesdale AT,McDonald OB,et a1.Aunique structure for epidermal growth factor receptor bound to GW572016(1apatinih):relationships among protein conformation,inhibitor off-rate,and receptor activity in tumor cells[J]. Cancer Res,2004,64(18):6652- 6659.
[8] Segota E,Bukowski RM.The promise of targeted therapy:Cancer drugs become more specific[J]. Cleve Clin J Med,2004,71(7):551-560.
[9] Amato RJ,Misellati A,Khan M,et a1.A phase Ⅱ trial of RAD001 in patients(Pts)with metastatic renal cell carcinoma(MRCC)[J].Proc Am Soc Clin Oncol,2006,24:224s.
[10] Needle MN.Safety experience with IMC-C225,an anti-epidermal growth factor receptor antibody[J]. Semin Oncol,2002,29(5 Suppl 14):S55-S60.
[11] Vannucchi MG.Receptors in interstitial cells of Cajal:identification and possible physiological roles[J].Microsd Res Tech,1999,47(5):325-33.
[12] Deininger MW,Goldman JM,Melo JV. The molecular biology of chronic myeloid leukemia[J]. Blood,2000,96(10):3343-3356.
[13] 陈拮,戴嫒嫒,汤致强. 小分子EGFR酪氨酸激酶抑制剂盐酸埃罗替尼[J]. 中国新药杂志,2005,14(10):1227-1229.
[14] 孙忠实,朱珠,韩风英. 酪氨酸激酶抑制剂一伊马替尼[J]. 中国药学杂志,2003,38(1):69-71.
[15] Rini B,Rixe O, Bukowski R, et a1. AG-013736, a multi-target tyrosine kinase receptor inhibitor,demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory,metastatic renal cell cancer(RCC)[J].Proc Am Soc Clin Oncol,2005,23:380s.
[16] Zhou Y,Li S,Hu YP,et a1. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyresine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis[J]. Cancer Res,2006,66(1):404-411.
(收稿日期:2010-03-09)
您现在查看是摘要介绍页，详见PDF附件(1867KB，3页)。